JP2023552852A5 - - Google Patents

Info

Publication number
JP2023552852A5
JP2023552852A5 JP2023535608A JP2023535608A JP2023552852A5 JP 2023552852 A5 JP2023552852 A5 JP 2023552852A5 JP 2023535608 A JP2023535608 A JP 2023535608A JP 2023535608 A JP2023535608 A JP 2023535608A JP 2023552852 A5 JP2023552852 A5 JP 2023552852A5
Authority
JP
Japan
Prior art keywords
gcc
seq
agent
heavy chain
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552852A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000852 external-priority patent/WO2022123307A1/en
Publication of JP2023552852A publication Critical patent/JP2023552852A/ja
Publication of JP2023552852A5 publication Critical patent/JP2023552852A5/ja
Pending legal-status Critical Current

Links

JP2023535608A 2020-12-09 2021-12-09 グアニル酸シクラーゼc(gcc)抗原結合剤の組成物及びその使用方法 Pending JP2023552852A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063123333P 2020-12-09 2020-12-09
US63/123,333 2020-12-09
PCT/IB2021/000852 WO2022123307A1 (en) 2020-12-09 2021-12-09 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023552852A JP2023552852A (ja) 2023-12-19
JP2023552852A5 true JP2023552852A5 (https=) 2024-12-17

Family

ID=80119244

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535608A Pending JP2023552852A (ja) 2020-12-09 2021-12-09 グアニル酸シクラーゼc(gcc)抗原結合剤の組成物及びその使用方法

Country Status (16)

Country Link
US (1) US20240033359A1 (https=)
EP (1) EP4259165A1 (https=)
JP (1) JP2023552852A (https=)
KR (1) KR20230130641A (https=)
CN (1) CN117015388A (https=)
AR (1) AR124289A1 (https=)
AU (1) AU2021397404A1 (https=)
CA (1) CA3204692A1 (https=)
CL (2) CL2023001667A1 (https=)
CO (1) CO2023009126A2 (https=)
EC (1) ECSP23050865A (https=)
IL (1) IL303541A (https=)
MX (1) MX2023006773A (https=)
PE (1) PE20240368A1 (https=)
TW (1) TW202237639A (https=)
WO (1) WO2022123307A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202519263A (zh) * 2019-03-21 2025-05-16 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
WO2024061170A1 (zh) * 2022-09-19 2024-03-28 广东菲鹏制药股份有限公司 抗人鸟苷酸环化酶c抗体及其试剂盒和应用
EP4594364A1 (en) * 2022-09-28 2025-08-06 Legend Biotech Ireland Limited Antibody and chimeric antigen receptors targeting gcc and methods of use thereof
CN116751303B (zh) * 2022-12-09 2023-12-26 华道(上海)生物医药有限公司 一种抗鸟苷酸环化酶2c的纳米抗体及其应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗hiv剤
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6005079A (en) * 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2353082A1 (en) 1998-11-03 2000-05-11 Centocor Inc. Modified antibodies and antibody fragments with increased duration of activity
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
CA2404431C (en) 2000-03-27 2011-06-07 Thomas Jefferson University Guanylyl cyclase c in the detection of stomach and esophageal cancers
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
SG10201407757XA (en) 2009-10-23 2015-01-29 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
US9156915B2 (en) * 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Cd20療法、cd22療法、およびcd19キメラ抗原受容体(car)発現細胞との併用療法
WO2018028647A1 (en) 2016-08-10 2018-02-15 Legend Biotech Usa Inc. Chimeric antigen receptors targeting bcma and methods of use thereof
KR20230148844A (ko) * 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
CA3093705A1 (en) * 2018-03-16 2019-09-19 Thomas Jefferson University Anti-gucy2c chimeric antigen receptor compositions and methods

Similar Documents

Publication Publication Date Title
JP2023552852A5 (https=)
JP2017535257A5 (https=)
JP2021534762A5 (https=)
JP2018506961A5 (https=)
JP2022512132A5 (https=)
JP2024518776A5 (https=)
JP2021514664A5 (https=)
JP2023504003A5 (https=)
JP2023540526A5 (https=)
JP2015172045A5 (https=)
JP2026041845A5 (https=)
JP2020501598A5 (https=)
JP2019505564A5 (https=)
JP2020510653A5 (ja) Ceaを標的にする多重特異性結合タンパク質
JP2021510521A5 (https=)
JP2020510422A5 (https=)
JP2017519501A5 (https=)
JP2017526339A5 (https=)
CN101432015A (zh) 功能性抗体
JP2022535553A5 (https=)
JP2020534830A5 (https=)
JP2023543493A5 (https=)
JP2024531409A5 (https=)
JP2023508174A5 (https=)
JP2019528677A5 (https=)